Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00388427
Other study ID # 06-038
Secondary ID CA180049
Status Completed
Phase Phase 1
First received October 13, 2006
Last updated May 27, 2015
Start date June 2007
Est. completion date February 2013

Study information

Verified date January 2014
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is an open-label, safety study of cetuximab and differing dose levels of dasatinib in adult patients with advanced solid malignancies. Cetuximab will be administered as an intravenous infusion weekly. Dasatinib will be taken orally, once a day, on a continuous schedule at differing dose levels. The primary objective of this study is to determine the toxicities and the maximum tolerated doses of dasatinib when combined with cetuximab for the treatment of advanced solid tumors.


Description:

This is an open-label, phase I study of cetuximab and differing dose levels of dasatinib in adult patients with advanced solid malignancies. Cetuximab will be administered as an intravenous infusion on a standard dose and schedule (weekly, with the first dose at 400 mg/m2 and all subsequent weekly doses at 250 mg/m2). Dasatinib will be administered orally on a continuous schedule at the following dose levels: 100 mg QD (once a day), 150 mg QD, and 200 mg QD. Three to six patients will be enrolled at each dose level, and the final recommended phase II cohort will be expanded to include up to 12 additional patients. The doses will be escalated in successive cohorts of patients. On cycle 1, dasatinib administration will start one day prior to cetuximab administration. One cycle will be defined as 21 days, and cycles will continue until progression of disease or intolerable toxicities occur. Peripheral blood samples and pharmacokinetic blood samples will be taken on days 0, 1, 15, and 16 of Cycle 1 only. In patients with accessible tumor that give consent, patients will undergo a baseline tumor biopsy and a repeat biopsy after 14-21 days of the first cycle.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date February 2013
Est. primary completion date July 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Histologically or cytologically confirmed solid malignancy which is recurrent or metastatic or resistant to therapy. Patients w/plan of surgery for recurrent disease post cetuximab/dasatinib are eligible providing that they receive at least 2 cycles of therapy and provide baseline and post-treatment tumor tissue for correlatives.

2. Any number of prior regimens but no prior EGFR or src inhibitors.

3. Age greater or equal to 18 years.

4. ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%).

5. Life expectancy greater than 12 weeks.

6. Patients must have normal organ and marrow function:

- leukocytes greater than or equal to 3,000/mcL

- absolute neutrophil count greater than or equal to 1,500/mcL

- platelets greater than or equal to 100,000/mcL

- total bilirubin within normal institutional limits

- AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of normal

- creatinine up to 1.5 x normal institutional limits

7. Ability to understand and the willingness to sign a written informed Consent document.

8. No concomitant medication that are CYP3A4 inducers or potent inhibitors and should not take proton pump inhibitors and H2 antagonists in the first cycle of therapy and should try to avoid taking proton pump inhibitors and H2 antagonists during rest of treatment period.

9. Sexually active women of childbearing potential must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized. All WOCBP must have a negative pregnancy test prior to first receiving investigational product.

Exclusion Criteria:

1. Chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.

2. Any other concurrent investigational agents.

3. Patients w/ untreated brain metastases. However, patients who have stable brain disease (should be off corticosteroids) at least 4 weeks after completion of appropriate therapy are eligible.

4. History of allergic reaction to monoclonal antibodies.

5. Inability to swallow oral medications unless patients use a feeding tube.

6. Uncontrolled angina or hypertension or any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes).

7. Prolonged QTc interval on pre-entry electrocardiogram (greater than 450 msec) on both the Fridericia and Bazett's correction.

8. Diagnosed or suspected congenital long QT syndrome.

9. Patients currently taking drugs that are generally accepted to have a risk of causing Torsades de Pointes including: quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, erythromycins, clarithromycin, chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.

10. Any other uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements.

11. History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrand's disease), diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).

12. HIV-positive patients receiving combination antiretroviral therapy.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Dasatinib (BMS-354825)
100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.
Cetuximab (Erbitux, C225)
Loading dose of IV 400 mg/m^2 on Day 1 of Cycle 1; IV 250 mg/m^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.

Locations

Country Name City State
United States University of Pittsburgh Cancer Institute - Hillman Cancer Center Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pittsburgh Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the toxicities and the maximum tolerated doses of dasatinib when combined with cetuximab for the treatment of advanced solid tumors Anticipated completion date December 2008 Yes
Secondary To determine the objective response rate and overall survival in patients enrolled in the study Anticipated completion date December 2008 No
Secondary To evaluate tissue biomarkers that relate to EGFR and Src signaling pathways on baseline tumor tissue and to study their modulation with cetuximab/dasatinib on post-treatment tumor tissue Anticipated completion date December 2008 No
Secondary To measure Src in peripheral blood mononuclear cells (PBMCs) before and after therapy Anticipated completion date December 2008 No
Secondary To evaluate EGFR gene copy number by FISH on baseline tumor tissue Anticipated completion date December 2008 No
Secondary To determine pharmacokinetic parameters of dasatinib in patients with and without feeding tubes Anticipated completion date December 2008 No
See also
  Status Clinical Trial Phase
Completed NCT01721148 - A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours Phase 1
Completed NCT00551096 - Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors Phase 1
Completed NCT01023737 - Hydroxychloroquine + Vorinostat in Advanced Solid Tumors Phase 1
Completed NCT01435096 - BN80927 in Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT01951846 - To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours Phase 1
Completed NCT01325558 - A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT01554371 - Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Phase 1/Phase 2
Recruiting NCT01286896 - Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT01309490 - Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients Phase 1/Phase 2
Completed NCT00635791 - Phase I Study of Vorinostat and Sorafenib in Advanced Cancer Phase 1
Completed NCT01376505 - Vaccine Therapy in Treating Patients With Metastatic Solid Tumors Phase 1
Completed NCT01611857 - Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach Phase 1/Phase 2
Completed NCT02843204 - Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors Phase 1/Phase 2
Completed NCT02853903 - Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors Phase 2
Completed NCT01618136 - An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT00801151 - Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer Phase 1
Completed NCT02786628 - Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
Completed NCT01184807 - Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors Phase 1
Completed NCT00969410 - A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases Phase 1
Completed NCT02857920 - Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors Phase 1/Phase 2